Paloma Partners’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Paloma Partners’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-30,289	Closed	-$35K	–	2706
2020 Q2	$35K	Buy	+30,289	New	+$32K	﹤0.01%	2014
2019 Q4	–	Sell	-161,245	Closed	-$134K	–	2685
2019 Q3	$134K	Sell	161,245 -68,555	-30%	-$52.3K	﹤0.01%	1812
2019 Q2	$197K	Buy	+229,800	New	+$212K	﹤0.01%	1546
2016 Q3	–	Sell	-85,992	Closed	-$292K	–	2406
2016 Q2	$292K	Buy	+85,992	New	+$395K	﹤0.01%	1779
2015 Q2	–	Sell	-2,350	Closed	-$43K	–	2090
2015 Q1	$43K	Buy	+2,350	New	+$52.9K	﹤0.01%	1151
2014 Q3	–	Sell	-2,663	Closed	-$75K	–	1588
2014 Q2	$75K	Buy	+2,663	New	+$80K	﹤0.01%	1048
2013 Q4	–	Sell	-10,000	Closed	-$164K	–	1369
2013 Q3	$164K	Buy	+10,000	New	+$116K	0.01%	769

Other funds holding CTIC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's CTIC Position: Q3 2020 in Review

Paloma Partners sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2020, closing a stake of 30,289 shares — an estimated $35K sold.

Paloma Partners first reported a position in CTIC in Q3 2013 and held it in 7 quarters. The position peaked at $292K in Q2 2016. 38 funds tracked by Wall St. Rank hold CTIC as of Q3 2020.

Paloma Partners reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2020 after selling out during the quarter.
Paloma Partners sold 30,289 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2020, an estimated $35K.
Paloma Partners first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2013 and held it in 7 quarters.
Paloma Partners's CTI BioPharma Corp. (DE) Common Stock position peaked at $292K in Q2 2016.
38 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.